Habte Yimer

4.1k total citations
48 papers, 270 citations indexed

About

Habte Yimer is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Habte Yimer has authored 48 papers receiving a total of 270 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Genetics, 20 papers in Pathology and Forensic Medicine and 20 papers in Hematology. Recurrent topics in Habte Yimer's work include Chronic Lymphocytic Leukemia Research (22 papers), Lymphoma Diagnosis and Treatment (16 papers) and Multiple Myeloma Research and Treatments (12 papers). Habte Yimer is often cited by papers focused on Chronic Lymphocytic Leukemia Research (22 papers), Lymphoma Diagnosis and Treatment (16 papers) and Multiple Myeloma Research and Treatments (12 papers). Habte Yimer collaborates with scholars based in United States, United Kingdom and Spain. Habte Yimer's co-authors include John M. Burke, Robert M. Rifkin, Jason M. Melear, Don A. Stevens, Mohit Narang, Edward A. Faber, Thomas S. Lin, Yana Lutska, Jeff P. Sharman and William Bensinger and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Habte Yimer

45 papers receiving 268 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Habte Yimer United States	9	156	136	106	78	75	48	270
Jana Mihályová Czechia	7	136 0.9×	84 0.6×	90 0.8×	57 0.7×	49 0.7×	16	251
Neil Came Australia	8	74 0.5×	186 1.4×	106 1.0×	106 1.4×	148 2.0×	17	308
Connie Qi Canada	8	137 0.9×	269 2.0×	236 2.2×	56 0.7×	76 1.0×	14	350
Elisa Genuardi Italy	9	110 0.7×	118 0.9×	114 1.1×	87 1.1×	51 0.7×	25	231
Lüder Hinrich Meyer Germany	10	116 0.7×	144 1.1×	181 1.7×	36 0.5×	59 0.8×	24	381
Even H. Rustad United States	9	147 0.9×	214 1.6×	159 1.5×	46 0.6×	39 0.5×	13	306
Alexandra Savell United States	7	98 0.6×	73 0.5×	78 0.7×	111 1.4×	143 1.9×	15	240
Jing Christine Ye United States	7	139 0.9×	82 0.6×	89 0.8×	35 0.4×	24 0.3×	20	262
Monica Testoni Switzerland	4	92 0.6×	120 0.9×	230 2.2×	87 1.1×	36 0.5×	7	321
Dejan Radeski Australia	9	140 0.9×	35 0.3×	164 1.5×	98 1.3×	34 0.5×	20	307

Countries citing papers authored by Habte Yimer

Since Specialization

Citations

This map shows the geographic impact of Habte Yimer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Habte Yimer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Habte Yimer more than expected).

Fields of papers citing papers by Habte Yimer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Habte Yimer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Habte Yimer. The network helps show where Habte Yimer may publish in the future.

Co-authorship network of co-authors of Habte Yimer

This figure shows the co-authorship network connecting the top 25 collaborators of Habte Yimer. A scholar is included among the top collaborators of Habte Yimer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Habte Yimer. Habte Yimer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shadman, Mazyar, John M. Burke, Jennifer L. Cultrera, et al.. (2025). Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results. Blood Advances. 9(16). 4100–4110. 4 indexed citations

Manda, Sudhir, Bertrand Anz, Christopher B. Benton, et al.. (2024). A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia. Hematological Oncology. 42(3). e3274–e3274. 6 indexed citations

Mascarenhas, John, Salman Otoukesh, Terrence Bradley, et al.. (2024). Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF). Blood. 144(Supplement 1). 998–998. 1 indexed citations

Castillo, Jorge J., Edwin Kingsley, Mohit Narang, et al.. (2023). Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States. SHILAP Revista de lepidopterología. 4(1). 301–304. 3 indexed citations

Kadia, Tapan M., Christopher B. Benton, Harry P. Erba, et al.. (2022). Trial in Progress: Phase 1b/2 Study of Alrizomadlin (APG-115), Alone or Combined with 5-Azacitidine (AZA), in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), or Myelodysplastic Syndrome (MDS). Blood. 140(Supplement 1). 11659–11660. 3 indexed citations

Yimer, Habte, Jason M. Melear, Edward A. Faber, et al.. (2022). Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study. Leukemia & lymphoma. 63(10). 2383–2392. 10 indexed citations

Godwin, John E., César O. Freytes, Michael B. Maris, et al.. (2021). Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) at Nonuniversity Medical Centers (NMCs): Initial Results from the Outreach Study in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL). Transplantation and Cellular Therapy. 27(3). S203–S204. 1 indexed citations

Danilov, Alexey V., Habte Yimer, Michael Boxer, et al.. (2021). Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine. Clinical Lymphoma Myeloma & Leukemia. 22(2). 121–128.

Manda, Sudhir, Bertrand Anz, Christopher B. Benton, et al.. (2021). Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia. Blood. 138(Supplement 1). 1265–1265. 3 indexed citations

10.

Allan, John N., Javier Pinilla‐Ibarz, Douglas E. Gladstone, et al.. (2021). Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica. 107(4). 984–987. 27 indexed citations

11.

Manda, Sudhir, Habte Yimer, Stephen J. Noga, et al.. (2020). Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib. Clinical Lymphoma Myeloma & Leukemia. 20(11). e910–e925. 11 indexed citations

12.

Shadman, Mazyar, Jeff P. Sharman, Moshe Levy, et al.. (2020). Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib. Blood. 136(Supplement 1). 51–52. 3 indexed citations

13.

Flinn, Ian W., David Andorsky, Jason M. Melear, et al.. (2020). Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study. Blood. 136(Supplement 1). 4–5. 2 indexed citations

14.

Witzig, Thomas E., Kami J. Maddocks, Sven de Vos, et al.. (2019). Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 37(15_suppl). 7519–7519. 12 indexed citations

15.

Witzig, T.E., Kami J. Maddocks, Sven de Vos, et al.. (2019). ACALABRUTINIB PLUS PEMBROLIZUMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A PHASE 1/2 STUDY. Hematological Oncology. 37(S2). 327–328. 6 indexed citations

16.

Rifkin, Robert M., Jason M. Melear, Edward A. Faber, et al.. (2019). Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study. Blood. 134(Supplement_1). 863–863. 9 indexed citations

17.

Yimer, Habte, Jason M. Melear, Edward A. Faber, et al.. (2018). Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM). Blood. 132(Supplement 1). 152–152. 9 indexed citations

18.

Yimer, Habte, Jason M. Melear, Edward A. Faber, et al.. (2017). Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM). Blood. 130. 1839–1839. 5 indexed citations

19.

Lonial, Sagar, Habte Yimer, María‐Victoria Mateos, et al.. (2016). KEYNOTE-185: A randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM). Annals of Oncology. 27. viii16–viii16. 2 indexed citations

20.

Yasenchak, Christopher A., Ahmad Halwani, Ranjana H. Advani, et al.. (2015). Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study. Blood. 126(23). 814–814. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact